KRAS G12C inhibitor 19

CAS No. 2649788-46-3

KRAS G12C inhibitor 19( —— )

Catalog No. M35195 CAS No. 2649788-46-3

KRAS G12C inhibitor 19 is a potent KRAS G12C inhibitor that demonstrates anti-tumor activity in cellular assays and inhibits tumor growth .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 126 Get Quote
5MG 186 Get Quote
10MG 280 Get Quote
25MG 526 Get Quote
50MG 753 Get Quote
100MG 1017 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    KRAS G12C inhibitor 19
  • Note
    Research use only, not for human use.
  • Brief Description
    KRAS G12C inhibitor 19 is a potent KRAS G12C inhibitor that demonstrates anti-tumor activity in cellular assays and inhibits tumor growth .
  • Description
    KRAS G12C inhibitor 19 is a potent inhibitor of KRAS G12C. KRAS G12C inhibitor 19 significantly inhibits tumor growth (extracted from patent WO2021118877A1).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Kras
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2649788-46-3
  • Formula Weight
    528.96
  • Molecular Formula
    C25H19ClF2N4O3S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (236.31 mM; Ultrasonic )
  • SMILES
    C(#N)C=1C2=C(C=CC(F)=C2SC1N)C=3C(Cl)=C4C(=CC3F)C(=O)N5[C@@](CCO4)(CN(C(C=C)=O)CC5)[H]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Serge Louis Boulet, et al. Kras g12c inhibitors. Patent WO2021118877A1.
molnova catalog
related products
  • Ganoderol B

    Ganoderol B is a potent β ±-glucosidase and angiotensin-converting enzyme inhibitor, with an IC(50) of β ±-glucosidase is 119.8 uM.

  • Z-Gly-Gly-Arg-AMC ac...

    Z-Gly-Gly-Arg-AMC acetate is a thrombase-specific fluorescent matrix for the detection of thrombin production in PRP and poor platelet plasma (PPP).

  • EcDsbB-IN-12

    EcDsbB-IN-12 targets disulfide bond forming enzyme,and is a novel potent specific inhibitor of EcDsbB.